Agenus divulga resultados de 2019 e tem como principal meta para 2020 submeter ao FDA o BLA do balstilimab (anti-PD-1) e zalifrelimab (anti-CTLA-4).

Leia mais em (em inglês): https://bit.ly/2vBVPEm

ReceptaBio e Agenus são parceiros no desenvolvimento de balstilimab (anti-PD-1) e zalifrelimab (anti-CTLA-4). A ReceptaBio possui direitos exclusivos de produção, desenvolvimento e comercialização para o Brasil, Argentina, Chile, Colômbia, Peru e Venezuela e royalties sobre as vendas líquidas.

===================

Agenus Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update.

Highlights:

- Balstilimab & zalifrelimab (anti-CTLA-4) demonstrate 26.5% response rates in an all-comer (non-biomarker selected) population with advanced cervical cancer;

- FDA grants Fast Track Designation for the investigation of combination balstilimab & zalifrelimab in relapsed / refractory metastatic cervical cancer;

- AGEN1181 +/- balstilimab (anti-PD-1) reveals a complete response and new partial responses in phase 1 clinical trial;

- Key Milestones Expected in 2020: 2 BLA filings for balstilimab (anti-PD-1) and zalifrelimab (anti-CTLA-4).

Read more: https://bit.ly/2vBVPEm

ReceptaBio and Agenus are partners in the development of balstilimab (anti-PD-1) and zalifrelimab (anti-CTLA-4). ReceptaBio has exclusive production, development and commercialization rights for Brazil, Argentina, Chile, Colombia, Peru and Venezuela and royalties over net sales.